Positive results from trial of cabozantinib plus nivolumab combination in untreated metastatic kidney cancer

Results from the pivotal phase 3 CheckMate-9ER clinical trial evaluating nivolumab (Opdivo) in combination with cabozantinib (Cabometyx) compared to sunitinib in previously untreated advanced or metastatic renal cell carcinoma (RCC) were released today. These top-line results were positive for the combination treatment, which improved progression-free survival, overall survival and objective response rate compared to sunitinib. […]

read more

Nivolumab for the treatment of metastatic non-clear cell renal cell carcinoma

Nivolumab alone and in combination with ipilimumab is used for the treatment of patients with metastatic renal cell carcinoma (RCC) in the second- and first-line, respectively. However, since patients with non-clear cell RCC are excluded from clinical trials, there is limited data on the effectiveness of nivolumab for the treatment of these patients. In a […]

read more

ASCO GU 2020: Immunotherapy combinations effective for brain metastases

Two small studies reported on patients whose kidney cancer had spread into the brain at the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium held in San Francisco last weekend. The first study was a real-world report of 17 patients with advanced kidney cancer in the brain. The patients were treated with ipilimumab and […]

read more

ASCO GU 2020: New drug, sitravatinib in combination with nivolumab for second-line treatment of advanced kidney cancer

The results from one of the first clinical trials of a combination of a new drug, sitravatinib, with nivolumab for the second-line treatment of advanced kidney cancer were presented at the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium in San Francisco last weekend. Sitravatinib is a type of drug called a tyrosine kinase inhibitor […]

read more

ASCO GU 2020: Five-year survival data for metastatic kidney cancer patients treated with nivolumab

Five-year follow-up results from the phase 3 CheckMate-025 study, which compared nivolumab (Opdivo) with everolimus in previously treated advanced or metastatic renal cell carcinoma (RCC), were presented at the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium in San Francisco last weekend. Nivolumab continues to show superior overall survival and objective response rates […]

read more

C-reactive protein as a potential predictive biomarker for kidney cancer

A recent study published in Science Direct describes how a change in blood C-reactive protein (CRP) levels during the early phase of nivolumab treatment for metastatic renal cell carcinoma (mRCC) may be used to predict survival among patients with mRCC. Read more in Science Direct here

read more

Nivolumab/ipilimumab combination extends treatment-free survival in kidney cancer patients

Immune checkpoint inhibitors (ICIs), such as nivolumab and ipilimumab have revolutionised the treatment for metastatic renal cell carcinoma (RCC). However, the most appropriate duration for immunotherapy treatment is not clear. In a recent analysis of the results from the phase III CheckMate 214 trial, all RCC patients randomised to receive the nivolumab/ipilimumab combination had longer […]

read more

PARP inhibitors, vaccines and combination therapies for kidney cancer

In this interview with OncLive, professor Sumanta Kumar Pal from City of Hope Hospital in California discusses the potential of poly ADP ribose polymerase (PARP) inhibitors, chimeric antigen receptor (CAR)-based products, vaccines, and novel drug combinations for the treatment of metastatic renal cell carcinoma (mRCC). Results from the phase Ib/II TiNivo study of the combination […]

read more

Alternative schedule ipilimumab plus nivolumab for first-line treatment of advanced kidney cancer

The combination of nivolumab with ipilimumab has been proven to be effective in the treatment of patients with metastatic renal cell carcinoma (RCC), and is available as a first line treatment via the Cancer Drugs Fund in England and Wales. In the current UK-based study (PRISM), which is still ongoing, researchers are assessing whether less […]

read more

IKCS 2019: Biomarkers in kidney cancer

In this interview taken from the International Kidney Cancer Symposium (IKCS) 2019 held in Miami, USA earlier this month, Dr Tian Zhang, from Duke University talks about existing and emerging immunotherapy biomarkers for kidney cancer, and the PEDIGREE study. Dr Zhang talks about PBRM1, PD-L1, and tumour mutational burden as prognostic biomarkers, and angiogenesis, CD8-infiltrating […]

read more
Showing 1 to 10 of 108 results
  TOP